Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis

Abstract

To establish the individualized treatment of patients with colorectal cancer, factors associated with chemotherapeutic effects should be identified. However, to the best of our knowledge, few studies are available on this topic, although it is known that the prognosis of patients and sensitivity to chemotherapy depend on the location of the tumor and that the tumor location is important for individualized treatment. In this study, primary tumors obtained from 1,129 patients with colorectal cancer were used to measure the mRNA expression levels of the following genes associated with the effects of standard chemotherapy for colorectal cancer: 5-fluorouracil (5-FU)-related thymidylate synthase (TYMS), dihydropyrimidine dehydrogenase (DPYD) and thymidine phosphorylase (TYMP); folate-related dihydrofolate reductase (DHFR), folylpolyglutamate synthase (FPGS) and gamma-glutamyl hydrolase (GGH); irinotecan-related topoisomerase I (TOP1); oxaliplatin-related excision repair cross-complementing 1 (ERCC1); biologic agent-related vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Large-scale population analysis was performed to determine the association of gene expression with the clinicopathological features, in particular, the location of the colorectal cancer. From the results of our analysis of the mRNA expression of these 10 genes, we noted the strongest correlation between DPYD and TYMP, followed by TYMS and DHFR. The location of the colorectal cancer was classified into 4 regions (the right- and left-sided colon, rectosigmoid and rectum) and was compared with gene expression. A significant difference in all genes, apart from VEGF, was noted. Of the remaining 9 genes, the highest expression of TYMS and DPYD was observed in the right-sided colon; the highest expression of GGH and EGFR was noted in the left-sided colon; the highest expression of DHFR, FPGS, TOP1 and ERCC1 was noted in the rectosigmoid, whereas TYMP expression was approximately equivalent in the right-sided colon and rectum, and higher than that in other locations. The data generated from this study may prove to be useful for the development of individualized chemotherapeutic treatments for patients with colorectal cancer, and will mean that the tumor location is taken into account.

Introduction

In 2012, colorectal cancer was estimated to be the third most common type of cancer after lung and prostate cancer in men, and the second most common after breast cancer in women worldwide. In terms of the mortality rate, it ranked fourth, after cancer of the lungs, liver and stomach in both men and women (1). Although colorectal cancer is principally treated by surgery, chemotherapy and radiotherapy may be given priority, depending on the stage of the disease. For many years, 5-fluo-rouracil (5-FU) alone or 5-FU and leucovorin were effectively used as chemotherapeutic agents for the treatment of colorectal cancer. However, the survival benefit in patients with metastatic colorectal cancer has been reported to be markedly increased by the combined use of chemotherapeutic agents, such as irinotecan and oxaliplatin with biological agents, such as bevacizumab for anti-vascular endothelial growth factor (VEGF) antibody therapy and cetuximab for anti-epidermal growth factor receptor (EGFR) antibody therapy, in addition to cytotoxic agents (2).

To increase the effectiveness of chemotherapy for patients with colorectal cancer, it is necessary to establish individualized treatment strategies and, therefore, identifying factors associated with the effects of chemotherapy for colorectal cancer also becomes important. Thymidylate synthase (TYMS), a 5-FU target, requires 5,10-methylenetetrahydrofolate (5,10-methylene-THF), a folate co-factor, as a methyl group donor and methylates deoxyuridine monophosphate (dUMP) to become deoxythymidine monophosphate (dTMP). It acts as a rate-limiting enzyme during DNA synthesis (3). As an active metabolite of 5-FU, 5-fluoro-dUMP (FdUMP) covalently links with TYMS and 5,10-methylene-THF, forming a ternary complex and inhibiting the TYMS response (3). Dihydropyrimidine dehydrogenase (DPYD) is a rate-limiting enzyme catalyzing the response during the first step of the catabolism of 5-FU (4). Thymidine phosphorylase (TYMP), which is associated with the metabolism of 5-FU, is an enzyme catalyzing the reversible phosphorolysis of 5-FU to 5-fluoro-2′-deoxyuridine. TYMP is identical to platelet-derived endothelial-cell growth factor and is thought to be involved in angiogenesis (5). Salonga et al (6) and Soong et al (7) reported that the mRNA or protein expression of TYMS, DPYD and TYMP was associated with the antitumor effects of 5-FU. Leucovorin is metabolized in vivo into 5,10-methylene-THF, strengthens the ternary complex of FdUMP, TYMS and 5,10-methylene-THF, and strengthens the antitumor effects of 5-FU (8). Dihydrofolate reductase (DHFR) catalyzes the conversion of dihydrofolate into tetrahydrofolate, which is an important step in the generation of 5,10-methylene-THF (3). In addition, folate is converted from the monoglutamate to the polyglutamate form by folylpolyglutamate synthase (FPGS) and can therefore be easily maintained within the cells, while the polyglutamate chain is cleaved by gamma-glutamyl hydrolase (GGH) and is converted into the monoglutamate form. It is thought that the catalyzing of opposite reactions by FPGS and GGH in folate metabolism is associated with the adjustment of folate levels in cells, as well as with the augmentation of the effects of 5-FU by leucovorin (9). Topoisomerase I (TOP1), a target enzyme of irinotecan, destroys the superhelicity observed in DNA during DNA metabolic processes, such as replication and transcription; consequently, TOP1 plays a role in the regulation of DNA topology (10). The association of excision repair cross-complementing 1 (ERCC1), reportedly associated with the effects of oxaliplatin, is an excision nuclease involved in the nucleotide excision repair of DNA and plays an important role in the repair of platinum-induced DNA adducts (11,12). Both TOP1 and ERCC1 maintain the normal structure of DNA and are important for DNA functionality. VEGF is a key mediator in angiogenesis, consisting of multiple steps, and its high-level expression is thought to be closely associated with tumor growth and metastasis (13). EGFR plays an important role in the signaling pathway of epithelial cell growth, and its activation is thought to be closely associated with tumor invasion, metastasis and angiogenesis (14). Both VEGF and EGFR play important roles in signaling pathways associated with cell growth, such as angiogenesis and proliferation.

It is well known that not only embryological, morphological, physiological and molecular features, but also the prognosis of patients and their sensitivity to chemotherapy depend on whether the primary lesion of colorectal cancer is located on the right or left side (15–18). Consequently, the location of the colorectal cancer is thought to be important for deciding individualized treatment for patients with colorectal cancer. However, to the best of our knowledge, to date, there are few studies available on the association between the location of the colorectal cancer and the level of expression of genes related to the effects of chemotherapy for colorectal cancer.

Previously, we performed large-scale population studies investigating TYMS and DPYD activity, as well as protein and mRNA expression in various types of solid tumors and reported basic data regarding the comparisons of assays and the level of expression, according to the carcinoma (19,20). In this study, primary tumors obtained from 1,129 patients with colorectal cancer who received no chemotherapy were used. After measuring the genes related to standard chemotherapy for colorectal cancer (TYMS, DPYD, TYMP, DHFR, FPGS, GGH, TOP1, ERCC1, VEGF and EGFR), a large-scale population analysis was performed for the purpose of determining the association with clinicopathological features, and in particular, the location of the colorectal cancer.

Patients and methods

Patients and samples

Between January 2008 and June 2012, we collected samples from primary tumor surgeries conducted on 2,017 patients with colorectal cancer in 39 hospitals across Japan. All the hospitals participated in this study after approval was obtained from the ethical review board of each hospital. Formalin-fixed paraffin-embedded (FFPE) tumor specimens were used for the measurement of mRNA expression. The primary lesions of 1,129 patients with colorectal cancer who did not receive any chemotherapy were analyzed for the mRNA expression of 10 target genes (TYMS, DPYD, TYMP, DHFR, FPGS, GGH, TOP1, ERCC1, VEGF and EGFR). Of these, 888 patients were not included in the analysis: 80 patients (4.0%) who received pre-operative chemotherapy; 6 patients (0.3%) who were diagnosed with non-colorectal cancer based on a final pathological examination; 630 patients (31.2%) for whom some of the 10 target genes were not analyzed, at the hospitals' request; 62 patients (3.1%) for whom none of the 10 target genes were analyzable due to an inadequate number of cancer cells in the FFPE tumor specimens; 110 patients (5.5%) for whom one or more targeted genes were not analyzable due to insufficient tumor volume or considerable variability in the measured values. In addition, not detectable (n.d.) results were included in the analyzed data. The clinicopathological features of the patients were investigated based on the Japanese classification of colorectal cancer: General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus, 7th edition (21).

Analysis of mRNA expression

The analysis of mRNA expression was performed as previously described (20). Briefly, the tumor sections (10-µm-thick) were stained with neutral fast red to enable histological visualization during laser-capture microdissection (PALM Robot-microbeam system; P.A.L.M. Microlaser Technologies AG, Munich, Germany), which was performed to ensure that only the tumor cells were collected. RNA was isolated from the FFPE tumor specimens using a novel proprietary procedure (Response Genetics, Los Angeles, CA, USA; United States Patent No. 6,248,535) and cDNA was obtained as previously described (22). The target cDNA sequences were amplified using quantitative polymerase chain reaction (qPCR) and a fluorescence-based real-time detection method [ABI PRISM 7900 Sequence Detection System (TaqMan); Applied Biosystems, Foster City, CA, USA] as previously described (23–25). The qPCR reaction mixture consisted of primers, dATP, dCTP, dGTP, dUTP, MgCl₂ and TaqMan buffer (all reagents were supplied by Applied Biosystems). The qPCR conditions were 50°C for 10 sec and 95°C for 10 min, followed by 42 cycles at 95°C for 15 sec and 60°C for 1 min. The mRNA expression levels were expressed as values relative to those of β-actin (ACTB), which was used as the internal reference. If the threshold cycle value for a gene of interest was ≥39.0, the expression for that gene was considered to be not detectable (n.d.), but in the case of ACTB it was measured normally.

Statistical analysis

mRNA expression was analyzed as a variable which was converted by using the natural logarithm and producing a normal distribution. Pearson's pairwise correlation coefficient was used to calculate the correlation of intergenic mRNA expression. For hierarchical cluster analysis of mRNA expression, the data were standardized using the means and standard deviation, while Ward's method was used to calculate the distance between clusters. For the equality of means, Welch's t-test or one-way analysis of variance (ANOVA) was performed. The analysis of the contingency table was performed using Fisher's exact test or χ² test. JMP version 9.0.2 (SAS Institute Japan Co., Ltd., Japan) was used for analysis, and a p-value <0.05 (two-tailed) was considered to indicate a statistically significant difference. The multiplicity of the test was not considered, as the analysis of this study was exploratory.

Results

Patient characteristics

The clinicopathological features of the 1,129 patients are presented in Table I. With regard to tumor location, the percentages obtained were similar for the right- and left-sided colon, and the rectum showed a slightly higher percentage. With regard to the depth of tumor invasion, tumor invasion of mucosa (M), tumor invasion of submucosa (SM) and tumor invasion of muscularis propria (MP) were equivalent to ≤T2 (Tis, T1 and T2) according to the TNM classification, 7th edition, developed by the Union for International Cancer Control (UICC), and accounted for a low percentage of 17.4% of the total. Tumor invasion of subserosa (SS), tumor invasion of serosa (SE), direct tumor invasion of other organs or structure in the intestine with serosa (SI), tumor invasion through muscularis propria into non-peritonealized, pericolic, or perirectal tissues (A) and direct tumor invasion of other organs or structure in the intestine without serosa (AI) were equivalent to ≥T3 (T3, T4a and T4b) according to the TNM classification and accounted for 79.8%. In addition, non-lymph node metastasis (N0) and lymph node metastases (≥N1) were 41.4 and 56.1%, respectively; stage I/II and stage III/IV disease were 34.0 and 59.6%, respectively, which indicated that the percentage of stage I/II disease tended to be lower.

Table I.

Clinicopathological features of the 1,129 patients.

Clinicopathological features	No. of patients	%
Age (mean, 66 years; median, 67 years; range, 24–94 years)
<67	525	46.5
≥67	558	49.4
No available data	46	4.1
Gender
Male	662	58.6
Female	459	40.7
No available data	8	0.7
Tumor location
Right-sided colon (C, A, T)	324	28.7
Left-sided colon (D, S)	317	28.1
Rectosigmoid	117	10.4
Rectum	358	31.7
Proctos	4	0.4
No available data	9	0.8
Histology
Well/moderately differentiated	1004	88.9
Poorly differentiated	35	3.1
Mucinos	32	2.8
Others	16	1.4
No available data	42	3.7
Lymphatic invasion
ly0	292	25.9
ly1, ly2, ly3	746	66.1
No available data	91	8.1
Venous invasion
v0	364	32.2
v1, v2, v3	670	59.3
No available data	95	8.4
Depth of tumor invasion
M, SM, MP	197	17.4
SS, SE, SI, A, AI	901	79.8
No available data	31	2.7
Lymph node metastasis
N0	467	41.4
N1, N2, N3	633	56.1
No available data	29	2.6
Stage
0	9	0.8
I	106	9.4
II	278	24.6
III	482	42.7
IV	191	16.9
No available data	63	5.6

Based on the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus (Japanese Society for Cancer of the Colon and Rectum, 7th edition) (21). Tumor location: C, cecum; A, ascending colon; T, transverse colon; D, descending colon; S, sigmoid colon. Depth of tumor invasion: M, tumor invasion of mucosa; SM, tumor invasion of submucosa; MP, tumor invasion of muscularis propria; SS, tumor invasion of subserosa; SE, tumor invasion of serosa, SI, direct tumor invasion of other organs or structure in the intestine with serosa; A, tumor invasion through muscularis propria into non-peritonealized, pericolic, or perirectal tissues; AI, direct tumor invasion of other organs or structure in the intestine without serosa.

Intergenic correlation and hierarchical cluster analysis

A summary of the results of the mRNA expression of the 10 target genes is presented in Table II, and the intergenic correlations obtained are listed in Table III. For the patients whose mRNA expression was not detectable (n.d.), the minimum mRNA expression of that gene was inserted as an alternative. The frequency of n.d. was as follows: TYMS, 1 (0.1%); DPYD, 35 (3.1%); TYMP, 9 (0.8%); DHFR, 1 (0.1%); FPGS, 2 (0.2%); GGH, 5 (0.4%); TOP1, 1 (0.1%); ERCC1, 2 (0.2%); VEGF, 1 (0.1%); and EGFR, 2 (0.2%) (data not shown). The frequency of n.d. was the highest in the DPYD gene but was in lower than 9 patients (0.8%) for the other genes; therefore, it was considered to have little influence on the results of the analysis.

Table II.

Summary of the mRNA expression levels of the 10 genes analyzed in this study in the 1,129 patients.

Gene	Gene expression/β-actin values			Log-transformed values
	Median	Min	Max	Mean	SD
TYMS	3.86	0.40	64.20	1.34	0.66
DPYD	0.28	0.03	4.61	−1.30	0.85
TYMP	2.72	0.22	45.30	1.02	0.79
DHFR	4.33	0.40	27.46	1.43	0.63
FPGS	0.59	0.15	4.49	−0.53	0.49
GGH	12.71	0.26	166.47	2.45	1.09
TOP1	2.79	0.41	107.07	1.02	0.52
ERCC1	1.67	0.27	18.06	0.52	0.55
VEGF	7.39	0.93	73.19	1.99	0.65
EGFR	1.35	0.11	55.07	0.29	0.61

Table III.

Correlations of the mRNA expression of the 10 log-transformed genes.

Gene	TYMS	DPYD	TYMP	DHFR	FPGS	GGH	TOP1	ERCC1	VEGF	EGFR
TYMS	1			0.596				0.427
DPYD		1	0.629
TYMP		0.629	1
DHFR	0.596			1		0.438	0.387	0.373
FPGS					1			0.456
GGH				0.438		1	0.487
TOP1				0.387		0.487	1		0.341
ERCC1	0.427			0.373	0.456			1
VEGF							0.341		1
EGFR										1

Only Pearson's correlations >0.3 are shown (p<0.0001).

Additionally, the strongest correlation was noted between DPYD and TYMP (r= 0.629), followed by TYMS and DHFR (r=0.596), GGH and TOP1 (r=0.487) and FPGS and ERCC1 (r=0.456). In a hierarchical cluster analysis of mRNA expression, the data were roughly classified into 2 groups: cluster A, in which the mRNA expression of all 10 genes was significantly low, and cluster B, in which the mRNA expression was significantly higher (Fig. 1 and Table IV). The associations between the 2 clusters and the clinicopathological features are summarized in Table V. A significant difference was noted between the histology, lymphatic invasion, lymph node metastasis and stage. There was a tendency for low-frequency mucinous adenocarcinoma in cluster B and the frequencies of non-lymphatic invasion (ly0), N0 and stage I/II disease were also higher in cluster B.

Figure 1.

Hierarchical clustering of 10 gene mRNA expression.

Table IV.

Log-transformed mRNA expression levels of two clusters.

Gene	Gene expression/β-actin values		p-value
	Cluster A (n=539)	Cluster B (n=590)
TYMS	1.04±0.61	1.61±0.60	<0.0001
DPYD	−1.62±0.88	−1.00±0.72	<0.0001
TYMP	0.82±0.81	1.20±0.72	<0.0001
DHFR	1.08±0.56	1.75±0.51	<0.0001
FPGS	−0.71±0.46	−0.37±0.46	<0.0001
GGH	1.97±1.11	2.90±0.86	<0.0001
TOP1	0.84±0.48	1.19±0.49	<0.0001
ERCC1	0.24±0.44	0.78±0.52	<0.0001
VEGF	1.69±0.59	2.26±0.59	<0.0001
EGFR	0.11±0.54	0.45±0.64	<0.0001

p-values were calculated by Welch's t-test.

Table V.

Comparison of clinicopathological features in two clusters of gene expression.

Clinicopathological features	No. of patients		p-value
	Cluster A	Cluster B
Age (years)
<67	252	273	0.394
≥67	253	305
Gender
Male	312	350	0.761
Female	221	238
Tumor location
Right-sided colon	150	174	0.305
Left-sided colon	156	161
Rectosigmoid	47	70
Rectum	177	181
Histology
Well/moderately differentiated	479	525	0.008
Poorly differentiated	15	20
Mucinous	24	8
Lymphatic invasion
ly0	129	163	0.039
ly1, ly2, ly3	383	363
Venous invasion
v0	171	193	0.241
v1, v2, v3	341	329
Depth of tumor invasion
T1, T2	102	95	0.238
T3, T4	424	477
Lymph node metastasis
N0	202	265	0.006
N1, N2, N3	327	306
Stage
I, II	166	218	0.013
III, IV	345	328

p-values were calculated by Fisher's exact test or χ² test.

Association of mRNA expression and clinicopathological features

The association between the mRNA expression of 10 target genes and the clinicopathological features is presented in Table VI. In relation to the location of the tumor, a significant difference was noted in all genes apart from VEGF when 4 locations were compared (the right- and left-sided colon, rectosigmoid and rectum), with the exception of the proctos; only 4 patients had a tumor at this location. Specifically, TYMS and DPYD showed the highest level of expression in the right-sided colon; GGH and EGFR showed the highest level of expression in the left-sided colon; DHFR, FPGS, TOP1 and ERCC1 showed the highest level of expression in the recto-sigmoid; TYMP showed approximately equivalent expression levels in the right-sided colon and rectum, where the expression was higher than in the other locations. On comparing two locations (right- and left-sided colon cancer) in patients with colon cancer only, a significantly high level of expression was noted in right-sided colon cancer for TYMS (fold change, 1.22; p=0.0001), DPYD (1.27-fold; p=0.001), TYMP (1.31-fold; p<0.0001), and FPGS (1.09-fold; p=0.020). By contrast, a significantly high level of expression was observed in left-sided colon cancer for the GGH (1.74-fold; p<0.0001), TOP1 (1.17-fold; p<0.0001) and EGFR (1.15-fold; p=0.006) genes, and no significant difference was noted for DHFR (1.06-fold; p=0.226), ERCC1 (1.08-fold; p=0.084) and VEGF (1.07-fold; p=0.191) (data not shown). For histology, there was a significant difference in 7 genes, excluding DHFR, VEGF and EGFR. For TYMS, DPYD and TYMP, the highest levels of expression were observed in patients with poorly differentiated adenocarcinoma, while the lowest levels of expression were observed in patients with well/moderately differentiated adenocarcinoma. For FPGS, GGH, TOP1 and ERCC1, the lowest levels of expression were observed in patients with mucinous adenocarcinoma; for FPGS and ERCC1, the highest level of expression was observed in patients with poorly differentiated adenocarcinoma; and for GGH and TOP1, the highest level of expression was observed in patients with well/moderately differentiated adenocarcinoma. As regards the depth of tumor invasion, a significantly higher level of expression was found in T1/2 as compared to T3/4 for TYMS, TYMP, DHFR, and ERCC1, while higher expression was found in T3/4 for VEGF only. For lymph node metastasis, there was a significant difference in TYMS, DHFR and ERCC1; a significantly higher level of expression was found in N0 than N≥1. For stage, there was a significant difference in TYMS, TYMP, DHFR and ERCC1, whereas a significantly higher level of expression was found in stage I/II than stage III/IV disease.

Table VI.

Associations between log-transformed mRNA expression levels and clinicopathological features.

Clinicopathological features	Log-transformed mRNA expression levels (means ± SD)
	TYMS	DPYD	TYMP	DHFR	FPGS	GGH	TOP1	ERCC1	VEGF	EGFR
Age (years)
<67	1.30±0.63	−1.33±0.84	1.03±0.75	1.42±0.63	−0.55±0.49	2.52±1.04	1.04±0.51	0.51±0.55	1.96±0.64	0.31±0.59
≥67	1.39±0.67	−1.24±0.87	1.01±0.82	1.48±0.60	−0.50±0.49	2.43±1.13	1.02±0.52	0.57±0.55	2.01±0.68	0.26±0.62
p-value	0.024	0.084	0.687	0.161	0.122	0.174	0.715	0.069	0.178	0.195
Gender
Male	1.34±0.65	−1.25±0.82	1.03±0.77	1.43±0.63	−0.52±0.48	2.53±1.07	1.06±0.53	0.51±0.54	2.02±0.65	0.30±0.61
Female	1.34±0.68	−1.36±0.90	1.00±0.82	1.44±0.63	−0.53±0.51	2.36±1.12	0.97±0.49	0.55±0.57	1.94±0.65	0.27±0.62
p-value	0.973	0.045	0.519	0.741	0.715	0.014	0.004	0.292	0.053	0.505
Tumor location
Right-sided colon	1.45±0.66	−1.20±0.92	1.11±0.87	1.48±0.63	−0.50±0.47	2.15±1.05	0.91±0.52	0.54±0.58	1.95±0.67	0.22±0.57
Left-sided colon	1.25±0.67	−1.44±0.78	0.84±0.73	1.42±0.60	−0.59±0.49	2.71±0.89	1.07±0.49	0.47±0.52	2.02±0.67	0.36±0.71
Rectosigmoid	1.43±0.60	−1.25±0.86	0.99±0.73	1.54±0.52	−0.45±0.48	2.65±1.08	1.11±0.43	0.66±0.58	1.98±0.55	0.34±0.64
Rectum	1.29±0.66	−1.26±0.83	1.11±0.75	1.35±0.67	−0.53±0.51	2.46±1.12	1.05±0.53	0.52±0.55	1.99±0.65	0.27±0.55
p-value	0.0002	0.004	<0.0001	0.014	0.028	<0.0001	<0.0001	0.016	0.610	0.022
Histology
Well/moderately	1.31±0.65	−1.35±0.81	0.98±0.76	1.42±0.62	−0.54±0.49	2.51±1.05	1.03±0.52	0.52±0.55	1.99±0.65	0.30±0.59
differentiated
Poorly differentiated	1.82±0.67	−0.52±1.18	1.80±1.03	1.47±0.82	−0.38±0.44	1.84±1.28	1.02±0.38	0.64±0.63	1.85±0.79	0.08±1.12
Mucinous	1.48±0.62	−0.70±0.96	1.22±0.65	1.26±0.70	−0.69±0.53	1.19±1.13	0.76±0.50	0.27±0.50	1.88±0.65	0.24±0.52
p-value	<0.0001	<0.0001	<0.0001	0.307	0.035	<0.0001	0.016	0.017	0.309	0.113
Lymphatic invasion
ly0	1.42±0.66	−1.26±0.90	1.16±0.75	1.45±0.66	−0.52±0.51	2.46±1.15	1.03±0.52	0.56±0.61	1.98±0.62	0.31±0.59
ly1, ly2, ly3	1.29±0.66	−1.32±0.84	0.94±0.79	1.39±0.62	−0.53±0.49	2.43±1.08	1.01±0.52	0.49±0.54	1.95±0.66	0.28±0.63
p-value	0.006	0.326	<0.0001	0.204	0.736	0.751	0.651	0.086	0.447	0.595
Venous invasion
v0	1.42±0.67	−1.21±0.89	1.08±0.79	1.45±0.63	−0.49±0.50	2.37±1.09	1.02±0.51	0.54± 0.59	1.94±0.63	0.28±0.61
v1, v2, v3	1.28±0.66	−1.36±0.83	0.96±0.78	1.38±0.64	−0.50±0.49	2.47±1.10	1.02±0.53	0.49± 0.54	1.96±0.65	0.30±0.63
p-value	0.001	0.012	0.026	0.117	0.048	0.179	0.876	0.218	0.608	0.668
Depth of tumor invasion
T1, T2	1.46±0.61	−1.25±0.95	1.13±0.79	1.54±0.58	−0.53±0.50	2.47±1.03	1.07±0.48	0.60±0.57	1.79±0.57	0.30±0.52
T3, T4	1.32±0.67	−1.32±0.82	0.98±0.78	1.40±0.64	−0.52±0.49	2.44±1.10	1.01±0.52	0.51±0.55	2.03±0.66	0.28±0.64
p-value	0.003	0.381	0.015	0.004	0.924	0.722	0.118	0.041	<0.0001	0.700
Lymph node metastasis
N0	1.43±0.68	−1.30±0.88	1.05±0.80	1.49±0.62	−0.51±0.49	2.50±1.09	1.04±0.53	0.59±0.58	1.97±0.67	0.26±0.56
N1, N2, N3	1.28±0.64	−1.30±0.82	0.99±0.77	1.38±0.63	−0.54±0.49	2.41±1.09	1.00±0.51	0.48±0.53	2.00±0.64	0.31±0.65
p-value	0.0002	0.889	0.193	0.004	0.486	0.186	0.214	0.001	0.366	0.195
Stage
I, II	1.43±0.67	−1.29±0.88	1.10±0.79	1.48±0.62	−0.51±0.50	2.48±1.09	1.03±0.53	0.58±0.58	1.95±0.66	0.27±0.56
III, IV	1.29±0.65	−1.32±0.83	0.95±0.79	1.39±0.63	−0.53±0.49	2.42±1.09	1.02±0.51	0.48±0.53	1.99±0.65	0.29±0.65
p-value	0.002	0.706	0.004	0.019	0.575	0.370	0.610	0.004	0.302	0.556

p-values were calculated by Welch's t-test or one-way ANOVA.

Comparison of clinicopathological features in right- or left-sided colon cancer

A comparison of the clinicopathological features between the patients with right- and left-sided colon cancer is presented in Table VII. A significant difference was found with respect to age, histology, lymph node metastasis and stage. The frequencies of elderly individuals, poorly differentiated and mucinous adenocarcinomas, N0 and stage I/II disease tended to be higher in right-sided colon cancer than left-sided colon cancer. The frequency of female patients tended to be higher for right- than left-sided colon cancer although the difference was not significant.

Table VII.

Comparison of clinicopathological features with the location of the colorectal cancer.

Clinicopathological features	No. of patients		p-value
	Right-sided colon	Left-sided colon
Age (years)
<67	105	159	<0.0001
≥67	205	148
Gender
Male	166	183	0.175
Female	151	133
Histology
Well/moderately differentiated	279	291	0.001
Poorly differentiated	16	9
Mucinous	17	2
Lymphatic invasion
ly0	88	73	0.197
ly1, ly2, ly3	211	224
Venous invasion
v0	115	96	0.145
v1, v2, v3	184	199
Depth of tumor invasion
T1, T2	40	32	0.382
T3, T4	278	282
Lymph node metastasis
N0	146	115	0.029
N1, N2, N3	173	196
Stage
I, II	118	93	0.041
III, IV	186	210

p-values were calculated by Fisher's exact test or χ² test.

Discussion

In this study, FFPE tumor specimens of primary tumors obtained from 1,129 patients with colorectal cancer were used. We measured mRNA expression levels of 10 genes associated with the effects of standard chemotherapy for colorectal cancer (TYMS, DPYD, TYMP, DHFR, FPGS, GGH, TOP1, ERCC1, VEGF and EGFR), and determined their association with clinicopathological features, in particular, the location of colorectal cancer.

From the results of mRNA expression analysis of the 10 genes included in this study, the strongest correlation was noted between DPYD and TYMP. Several studies have reported a similar correlation between expression levels in colorectal cancer (26–33). DPYD and TYMP encode enzymes related to the metabolism of 5-FU, and it seems likely that the expression levels of these genes in colorectal cancer tissues are co-regulated. In addition, the results from this study indicate a weaker correlation between TYMS and DHFR than that between DPYD and TYMP. Uetake et al also reported a similar correlation in stage III colon cancer (33). Considering that DHFR plays an important role in the generation of 5,10-methylene-THF as a co-factor of the TYMS response, it is plausible that the level of gene expression of both enzymes is correlated.

It has previously been reported that colorectal cancer, particularly colon cancer, exhibits embryologic, morphologic, physiologic and molecular differences between the right and left sides, which leads to differences in the prognosis of patients and their sensitivity to chemotherapy (15–18). In relation to the clinicopathological features, in these studies, it has been posited that the numbers of elderly individuals, women, mucinous adenocarcinoma, high grade (poorly differentiated/undifferentiated) and negative lymph node metastasis is higher in right- than left-sided colon cancer. In our study, similar, reproducible results were noted. As regards the molecular features, a microsatellite instability phenotype (MSI⁺) and CpG island methylator phenotype (CIMP⁺) are common in right-sided colon cancer, whereas chromosomal instability is common in left-sided colon cancer (15–18). Kawakami et al (34) analyzed the association between the CIMP⁺ status and the expression level of gene-related folate and nucleotide metabolism in the primary tumors of 114 patients from Australia with colorectal cancer. They reported that the low-level expression of GGH and high-level expression of TYMP were very strongly associated with CIMP⁺ and CIMP⁺-related clinicopathological and molecular features. They also reported that a significantly higher level of TYMP expression and a significantly lower level of GGH expression were found in right- as compared to left-sided colorectal cancer (34). Moreover, they pointed out the possibility that low-level GGH expression may lead to the maintenance of folate in the polyglutamate form in the cells, which is associated with DNA hypermethylation, and that 5-FU plus leucovorin therapy may then be more effective (34). In a study of 76 Japanese patients with stage II/III colorectal cancer, Sadahiro et al reported that a significantly high level of TYMP expression was found in cases of right rather than left-sided colorectal cancer and that preoperative uracil-tegafur (UFT) plus leucovorin therapy resulted in a significantly strong histological response (35). In the present study, in relation to right-sided colon cancer, we noted a significantly higher level of TYMP expression and a lower level GGH expression than in left-sided colon cancer. Considering these results, it may be worthwhile to determine the physiological significance of TYMP and GGH expression in patients with colorectal cancer in the future, in order to examine the hypothesis that 5-FU-based chemotherapy combined with leucovorin may be more effective in cases of right-sided colon cancer.

Ricciardiello et al reported that TYMS protein expression, as assessed by immunohistochemistry (IHC), did not differ significantly between right- and left-sided colorectal cancer, but a significantly high level of expression in MSI⁺ colorectal cancer was noted (36). Jensen et al also reported that the protein expression of TYMS (studied by IHC) was significantly high in MSI⁺ colorectal cancer (37). On the other hand, Sinicrope et al reported that there was no correlation between the MSI⁺ status and TYMS protein expression (as measured by IHC) (38). Thus, the association between TYMS protein expression and the MSI⁺ status remains controversial. In our study, as regards TYMS, its mRNA expression was found to be higher in right-sided colon cancer in which MSI⁺ was common, than in left-sided colon cancer. The analysis of the clinicopathological features of all the patients with colorectal cancer in this study revealed a high level of TYMS expression in the elderly, those with poorly differentiated adenocarcinoma and N0, which are common in right-sided colon cancer. However, as regards the association between TYMS expression and the location of colorectal cancer, further studies, which will include the association of TYMS with molecular features, such as the MSI⁺ status, are warranted in the future.

Recently, Missiaglia et al performed gene expression analysis of a colon cancer dataset on 914 patients who were registered in The Cancer Genome Atlas (TCGA) collection and Pan European Trial Adjuvant Colon Cancer (PETACC3) adjuvant chemotherapy trial. According to their study, the expression of EGFR and human epidermal growth factor receptor 2 (HER2) was advanced in left- rather than right- sided colon cancer, which activated EGF signaling, and the usefulness of anti-EGFR agents was suggested (39). Similarly, the results of our study demonstrated that a significantly higher level of EGFR expression was noted in left- rather than right-sided colon cancer. Hence, it is necessary to perform research on individualized treatment which combines the location of colorectal cancer and EGFR expression levels with the mutation status of KRAS and BRAF, as well as EGFR inhibitors.

Loupakis et al analyzed three independent cohorts in order to examine the association between the primary tumor of metastatic colorectal cancer and the efficacy of first-line chemotherapy. They reported that patients with primary tumors on the left side of the colon achieved significantly superior overall survival than those with primary tumors on the right side (40). They also analyzed gene expression in an exploratory manner using the archival series of 181 independent primary tumor samples. They inferred that the mRNA expression of ERCC1 was significantly higher in right- rather than left-sided colorectal cancer, although the mRNA expression level of VEGF ligands A, B and C, as well as VEGF receptors 1 and 2 showed no difference between right- and left-sided colorectal cancer. This is, perhaps, one of the factors involved in chemo-resistance in patients with right-sided colorectal cancer (40). In our study, although VEGF exhibited few differences in the level of expression according to the location of the tumor and the expression of ERCC1 was the lowest in the patients with left-sided colon cancer, the level of expression for ERCC1 was the highest in the rectosigmoid. Additionally, for ERCC1, there was no significant difference in the comparison between right- and left-sided colon cancer. Further research on the differences in sensitivity to oxaliplatin between patients with right- and left-sided colorectal cancer and the association with ERCC1 expression is warranted.

In our analysis of the association between gene expression and five factors related to the extent of cancer, namely lymphatic invasion, vein invasion, depth of tumor invasion, lymph node metastasis and stage, a significant difference was noted in all the five factors for TYMS; whereas DPYD, TYMP, DHFR, FPGS, ERCC1 and VEGF showed a significant difference in 1–4 factors. Of these, with the exception that the VEGF gene showed a significantly higher level of expression in T3/4 than T1/2, high-level expression was found in the group at a less-advanced stage rather than the group in the more advanced stages of cancer. This tendency is consistent with the results of the hierarchical cluster analysis. However, a comparison of patient characteristics was made between the 1,129 Japanese patients with colorectal cancer in our study and the data from 30,002 patients who were registered with the Japanese Society for Cancer of the Colon and Rectum between 1993 and 1997 (41), as well as the data from 621 patients who were registered in a single institution in Japan between 1992 and 2002 (42). This comparison revealed that, although age, gender, tumor location and histology had generally similar distributions, the percentages of T1/2, N0 and stage I/II were clearly low, and as a whole, the stage of cancer tended to be more advanced in our study. Consequently, it is likely necessary to consider the data on the association between gene expression levels in this study and the clinicopathological features associated with the progress of cancer with caution.

In this large-scale population study, we clarified the association between the mRNA expression of genes associated with the effects of standard chemotherapy for colorectal cancer and clinicopathological features, particularly the location of the colorectal cancer. It is hoped that the results of this study will become useful reference data for conducting research on individualized chemotherapy for colorectal cancer that takes into consideration the location of colorectal cancer.

Appendix

Collaborating hospitals: Chiba University Hospital, Fujita Health University Hospital, Gifu University Hospital, Hachioji Digestive Disease Hospital, Handa City Hospital, Himeji Medical Center, Hyogo Prefectural Kakogawa Medical Center, JCHO Kobe Central Hospital, Kanto Rosai Hospital, Keio University Hospital, Kinki University Hospital, Kitano Hospital, Kobe City Medical Center General Hospital, Kobe City Medical Center West Hospital, Kohsei Chuo General Hospital, Nagoya University Hospital, National Center for Global Health and Medicine Center Hospital, Nihon University Itabashi Hospital, Niitsu Medical Center Hospital, Omori Red Cross Hospital, Osaka Rosai Hospital, Osaka University Hospital, Saitama Medical Center, Sakai City Hospital, Sendai Red Cross Hospital, Showa University Fujigaoka Hospital, Showa University Hospital, The Jikei University Hospital, Tohoku Rosai Hospital, Tohoku University Hospital, Toho University Omori Medical Center, Tokushima Red Cross Hospital, Tokyo Medical University Hachioji Medical Center, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo Metropolitan Tama Medical Center, Totsuka Kyoritsu Second Hospital, Toyohashi Municipal Hospital, University of Yamanashi Hospital, Yamaguchi University Hospital.